Supplementary Figure S5 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Supplementary Figure S5. DBPR728 is efficacious in multiple c-MYC overexpressing preclinical tumor models. (A) Growth curve of NCI-H446 xenografts in NU/NU mice dosed with vehicle (10 ml/kg, 5W) or alisertib (50 mg/kg, 5W) for two weeks. The vehicle control is the same as the one in Fig. 3D. Amp, amplified. (B) Summary of preclinical tumor models used for DBPR728 and alisertib treatment. (C) Comparison of treatment efficacy between DBPR728 and alisertib in D341 (medulloblastoma, c-MYC amplified), SNU-398 (HCC, c-MYC overexpression) and PSN-1 (pancreatic cancer, c-MYC amplified) preclinical mouse models. OE, overexpression. (A, C) Errors are mean ± SEM.